Table 2. Demographics by epoch and surgical approach.
| Pre-pandemic | Pandemic | p-value | |
|---|---|---|---|
| Dates | 3/1/2019–1/31/2020 | 3/1/2020–1/31/2021 | NA |
| Patients (n = 295) | 163 | 132 | NA |
| Total Operations (n = 317) | 172 (54%) | 145 (46%) | NA |
| Mean Age (±SD) | 53.2±15.8 | 52.3±17.6 | 0.63 |
| Female | 95 (58.3%) | 69 (52.3%) | 0.35 |
| Prior Surgery | 39 (23.9%) | 34 (25.8%) | 0.79 |
| Emergent Surgery | 11 (6.4%) | 9 (6.2%) | 1.0 |
| Craniotomy Cohort | |||
| Patients (n = 163) | 82 | 81 | NA |
| Total Operations (n = 179) | 91 | 88 | NA |
| Mean Age (±SD) | 57.2±14.9 | 55.2±17.6 | 0.43 |
| Prior Surgery | 21 (25%) | 23 (28%) | |
| ASA | 0.28 | ||
| 1 | 4 (4%) | 1 (1%) | |
| 2 | 22 (25%) | 21 (24%) | |
| 3 | 61 (67%) | 57 (65%) | |
| 4 | 4 (4%) | 9 (10%) | |
| Pathology | |||
| Meningioma | 33 (36%) | 20 (23%) | |
| Glioma | 31 (34%) | 32 (36%) | |
| Metastatic Tumor | 15 (17%) | 20 (23%) | |
| Schwannoma | 3 (3%) | 4 (4%) | |
| Other* | 9 (10%) | 12 (14%) | |
| Endonasal Cohort | |||
| Patients (n = 132) | 79 | 53 | NA |
| Total Operations (n = 138) | 81 | 57 | NA |
| Mean Age (±SD) | 49.1±15.7 | 48.1±16.9 | 0.73 |
| Prior Surgery | 18 (23%) | 11 (21%) | 0.83 |
| ASA | 0.70 | ||
| 1 | 1 (1%) | 1 (2%) | |
| 2 | 37 (46%) | 22 (39%) | |
| 3 | 43 (53%) | 34 (59%) | |
| Pathology | |||
| Pituitary Adenoma | 52 (64%) | 39 (68%) | |
| Meningioma | 7 (9%) | 4 (7%) | |
| Craniopharyngioma | 7 (9%) | 1 (2%) | |
| Rathke’s Cleft Cyst | 5 (6%) | 8 (14%) | |
| Chordoma | 3 (3%) | 1 (2%) | |
| Other* | 7 (9%) | 4 (7%) |
For Craniotomy, other includes: arachnoid cyst, chordoma, pituitary adenoma, pineal parenchymal tumor, germinoma, neuroblastoma, RCC, dermoid cyst, epidermoid cyst, colloid cyst, sinonasal and neuroendocrine carcinoma, hemangioblastoma, hemangiopericytoma. For Endonasal other includes: sinonasal carcinoma, germinoma, glioma, epidermoid cyst, chondrosarcoma, granular cell tumor, ameloblastoma.